Divisadero Street Capital Management LP Makes New $2.38 Million Investment in Evolus, Inc. $EOLS

Divisadero Street Capital Management LP purchased a new stake in Evolus, Inc. (NASDAQ:EOLS) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 388,231 shares of the company’s stock, valued at approximately $2,384,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Brevan Howard Capital Management LP bought a new stake in shares of Evolus in the 3rd quarter valued at $244,000. Bank of America Corp DE boosted its stake in Evolus by 120.7% during the third quarter. Bank of America Corp DE now owns 266,115 shares of the company’s stock worth $1,634,000 after acquiring an additional 145,546 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in Evolus in the third quarter worth $48,000. Creative Planning bought a new stake in Evolus in the third quarter valued at $138,000. Finally, Prospect Capital Advisors LLC acquired a new position in shares of Evolus during the third quarter valued at about $1,278,000. 90.69% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Stifel Nicolaus reduced their target price on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Mizuho set a $15.00 price target on Evolus in a research note on Wednesday, February 4th. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Wall Street Zen cut Evolus from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, BTIG Research restated a “buy” rating and set a $13.00 price objective on shares of Evolus in a report on Wednesday, March 4th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Evolus presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Stock Performance

Shares of EOLS opened at $5.01 on Monday. The firm has a market capitalization of $325.95 million, a P/E ratio of -6.19 and a beta of 1.02. Evolus, Inc. has a 52 week low of $4.09 and a 52 week high of $13.66. The stock has a 50 day moving average price of $4.89 and a two-hundred day moving average price of $6.13.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to analysts’ expectations of $89.58 million. On average, equities analysts forecast that Evolus, Inc. will post -0.61 earnings per share for the current year.

Insiders Place Their Bets

In other Evolus news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the transaction, the insider directly owned 354,388 shares in the company, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.10% of the company’s stock.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.